This inventor holds 2 USPTO granted patents. Top assignees: Cancer Research Malaysia, University of Southampton. Active years: 2022-2026.
Company Filing History:
2 out of 2 
1 out of 252 
Years Active: 2022-2026
Title: Kue Peng Lim: Innovator in Cancer Immunotherapy
Introduction
Kue Peng Lim is a notable inventor based in Selangor, Malaysia. He has made significant contributions to the field of cancer research, particularly in the development of immunogenic peptide compositions. His work aims to enhance the immune response against cancer, showcasing the potential of innovative therapies in oncology.
Latest Patents
Kue Peng Lim holds a patent for an immunogenic peptide composition. This invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. The peptide composition includes at least a Four-jointed Box 1 peptide and a Melanoma Antigen family D4b peptide. Furthermore, the invention encompasses the use of this peptide composition and a peptide vaccine for inducing the anti-cancer immune response in the subject.
Career Highlights
Kue Peng Lim is currently associated with Cancer Research Malaysia, where he continues to advance his research in cancer immunotherapy. His dedication to this field has positioned him as a key figure in the development of novel therapeutic strategies aimed at combating cancer.
Collaborations
Kue Peng Lim collaborates with esteemed colleagues such as Chai Phei Gan and Sathibalan Ponniah. These partnerships enhance the research efforts at Cancer Research Malaysia, fostering innovation and progress in cancer treatment.
Conclusion
Kue Peng Lim's contributions to cancer research through his innovative peptide compositions highlight the importance of scientific advancements in the fight against cancer. His work exemplifies the potential of targeted immunotherapy in improving patient outcomes.